Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of the Cassiopeia trial on daratumumab in transplant eligible multiple myeloma (MM) patients. The trial compares bortezomib, thalidomide, dexamethasone (VTD) followed by stem cell transplantation, followed by two cycles of consolidation therapy with VTD with or without daratumumab (NCT02541383). The primary endpoint is stringent complete remission (CR). Within the same study, there is a second randomization with daratumumab maintenance for two years versus no maintenance. The goal is to show that the addition of daratumumab will improve the quality of response and therefore progression-free survival and further, that daratumumab could be important in the maintenance setting. According to Prof Moreau, this study is pivotal for the approval daratumumab in the context of stem cell transplantation. The enrollment for the trial will be completed in quarter one of 2017 and first results cannot be expected before 2018.
Recorded at the Myeloma 2016 meeting held in Boston, MA.